Figure 1.
Immune response after vaccination with the EGF-based vaccine. (A) Kinetics of the anti-EGF antibody titers (geometric mean) during the study period. (B) Frequency of patients showing seroconversion on time. GAR: Good Antibody Responder (antibody titers ≥1:4000); SGAR: Super-Good Antibody Responder (antibody titers ≥1:64,000); PAR: Poor Antibody Responder (antibody titers <1:4000).